IN8bio, Inc. has announced updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 trials evaluating DeltEx Drug-Resistant Immunotherapy $(DRI)$ gamma-delta (γδ) T cells in newly diagnosed glioblastoma (GBM). The results were presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting. The data showed that repeat-doses of DeltEx DRI γδ T cells nearly doubled median progression-free survival (mPFS) to 13.0 months compared to 6.6 months in a standard-of-care $(SOC)$ control cohort. Median overall survival (mOS) was reported at 17.2+ months as of December 31, 2025, compared to 13.2 months for SOC. The treatment demonstrated a favorable safety profile, with no treatment-related severe adverse events or dose limiting toxicities observed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623484-en) on January 12, 2026, and is solely responsible for the information contained therein.